CNS/Neurology

MacDonald SC, Rivero-Ferrer E, Bell EJ, Franklin J, Hardy J, Margulis AV, Seals R, Yang R, Seeger J, Straghan E, Asomaning K. A retrospective cohort database study to evaluate the safety of rimegepant exposure during pregnancy. Poster to be given at the 38th Annual Meeting of the Society for Pediatric and Perinatal Epidemiologic Research; June 9, 2025. Boston, MA.


Abstract not available at this time.

Raza S, Heyes A, Leonard C, D'Souza V, Carney R, Mackie D, Gelinas D, Swijsen A. Analysis of the burden of illness, treatment, and health disparities in amyotrophic lateral sclerosis. Poster presented at the ISPOR 2025; May 15, 2025. Montréal, Canada.


OBJECTIVES: The aim of this review is to identify information in the literature on burden of illness and treatment of amyotrophic lateral sclerosis (ALS) and to highlight disparities in the disease and management.

Shirneshan E, Smith E, Shewale A, Stokes J, Kosa K, DiBenedetti D. Patient and caregiver experiences with ischaemic stroke: results from a qualitative study. Poster presented at the 11th European Stroke Organization Conference (ESOC) 2025; May 21, 2025. Helsinki, Finland.


BACKGROUND AND AIMS: Qualitative research was conducted to understand experiences of recovery from ischaemic stroke and identify key treatment outcomes from the perspective of patients, caregivers, and clinicians.

Paulsen R, (Demuro) Romano C, Frangiosa T, Mordin M, Dardis GJ, DiBenedetti D, Petersen RC, Cummings JL. How do we put meaning into meaningful benefit? Perspectives from the lived experience - Commentary. Alzheimers Dement (NY). 2025 May 14;11(2):e70095. doi: 10.1002/trc2.70095


Bagnato F, Mordin M, Greene N, Mahida S, van Wingerden J. Associations between chronic active lesions and clinical outcomes in multiple sclerosis: a systematic literature review. J Manag Care Spec Pharm. 2025 May 13;1-28. doi: 10.18553/jmcp.2025.24294


Rao S, McQuay LJ, Forns J, MacKay R, Danysh HE, Doshi D, Abler V, Anthony MS, Layton JB. Evaluation of mortality in users of pimavanserin compared with other atypical antipsychotics in patients with Parkinson's disease psychosis: an update. Drug Saf. 2025 Apr 9. doi: 10.1007/s40264-025-01543-8


INTRODUCTION: Pimavanserin is the only antipsychotic medication approved in the United States to specifically treat hallucinations and delusions associated with Parkinson’s disease psychosis (PDP).

Layton JB, Forns J, McQuay LJ, Danysh HE, Dempsey C, Anthony MS, Turner ME. Plain language summary of mortality rates of patients with Parkinson's disease psychosis who were treated either with pimavanserin or with different second-generation (atypical) antipsychotics. Futur Neurol. 2025 Feb 28;20(1). doi: 10.1080/14796708.2025.2463315


Abstract not available at this time.

Brubaker M, Bratlee-Whitaker E, Brown TM, Partida A, Bucior I, Patel M, Clevenger C. Linguistic validation of the agitation in Alzheimer's screener for caregivers (AASC™), a novel tool based on the IPA definition of agitation in cognitive disorders. Poster presented at the 2024 International Psychogeriatric Association (IPA) Conference; September 25, 2024. Greenville, SC. [abstract] Int Psychogeriatr. 2024 Nov 27; 36(S1):79. doi: 10.1017/S1041610224001832


Hellwig K, Magyari M, MacDonald TM, Cesta CE, Wergeland S, Leinonen MK, Ornoy A, Vukusic S, Lauer A, Zhou X, Kawai A, Weinrib R, Arana A, Boumenna T. A multi-country cohort database study to assess pregnancy and infant outcomes after potential maternal or paternal exposure to cladribine tablets in the treatment of multiple sclerosis: the CLEAR study methods and status update1. Ther Adv Neurol Disord. 2025 Jan 27;18:175628642. doi: 10.1177/17562864241310996


BACKGROUND: Cladribine tablets are contraindicated during pregnancy; therefore, safety data on pregnancies exposed to this treatment are limited. CLEAR collects and describes pregnancy outcomes in this understudied population.

Bhushan NL, DeMuro Romano C, Gras-Najjar J, Reno J, Rockwood N, Quattrone W, Adams ET, Kelly B, McLeod L, Bhavnani SP, Bocell FD, Campbell M, Kontson K, Reasner D, Zhang C, Retzky S. Remote-use applications of the amyotrophic lateral sclerosis functional rating scale-revised clinical outcome assessment tool: a scoping review. Value Health. 2024 Oct;27(10):1454-65. doi: 10.1016/j.jval.2024.05.005


Subscribe to CNS/Neurology

How Can We Help You?